TABLE 4.

Proportion of days without treatment (%DwT) of each primary antipsychotic over the 12 months after inclusion, among patients with at least 12 months of dispensing (n = 9,997).

Primary antipsychotic	N (%)	Mean%DwT (StD)	Median%DwT (Q1–Q3)
Risperidone	1,970(19.7%)	22.7 (21.1)	17.8(2.7−38.3)
Cyamemazine	1,897(19.0%)	21.0 (21.4)	14.6(1.6−34.3)
Olanzapine	1,190(11.9%)	13.0 (19.1)	3.0(0.0−17.8)
Tiapride	806(8.1%)	18.1 (19.5)	9.9(1.4−28.8)
Haloperidol	769(7.7%)	20.2 (19.8)	15.5(2.7−32.1)
Aripiprazole	608(6.1%)	16.5 (20.2)	7.7(0.0−26.0)
Sulpiride	538(5.4%)	18.4 (22.1)	8.5(1.1−30.4)
Amisulpride	453(4.5%)	21.1 (19.9)	15.3(3.3−34.5)
Quetiapine	356(3.6%)	13.4 (19.5)	4.2(0.0−17.8)
Loxapine	273(2.7%)	17.1 (19.8)	9.3(0.8−27.7)
Levomepromazine	250(2.5%)	16.9 (20.6)	6.9(0.6−28.5)
Clozapine	161(1.6%)	10.6 (15.0)	3.3(0.0−17.5)
Pipamperone	137(1.4%)	11.5 (14.8)	3.8(0.0−17.8)
Zuclopenthixol	135(1.4%)	17.5 (17.5)	10.7(2.2−28.8)
Chlorpromazine	87(0.9%)	26.4 (20.5)	20.3(9.6−39.4)
Periciazine	84(0.8%)	17.9 (19.8)	8.7(2.5−32.9)
Fluphenazine	82(0.8%)	15.8 (19.7)	7.3(0.0−26.3)
Flupentixol	52(0.5%)	13.2 (18.4)	3.0(0.0−19.5)
Pipotiazine	51(0.5%)	11.2 (16.1)	3.8(0.0−15.6)
Paliperidone	38(0.4%)	9.0 (13.5)	2.6(0.0−12.6)
Pimozide	37(0.4%)	10.7 (16.1)	3.3(0.6−11.8)
Carpipramine	22(0.2%)	20.2 (20.1)	15.1(4.7−26.0)
Penfluridol	1(0.0%)	14.2(−)	14.2(14.2−14.2)